seretide diskus 50mcg - 100mcg /dosis polvo para inhalacion oral.
glaxosmithkline llc. - salmeterol (xinafoato) - salmeterol (xinafoato)....50 mcg / fluticasona propionato....100 mcg.
requip- ropinirole tablet, film coated
glaxosmithkline llc - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 0.25 mg - requip is indicated for the treatment of parkinson’s disease. requip is indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). requip is contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. risk summary there are no adequate data on the developmental risk associated with the use of requip in pregnant women. in animal studies, ropinirole had adverse effects on development when administered to pregnant rats at doses similar to (neurobehavioral impairment) or greater than (teratogenicity and embryolethality at >36 times) the mrhd for parkinson’s disease. ropinirole doses associated with teratogenicity and embryolethality in pregnant rats were associated with maternal toxicity. in pregnant rabbits, ropinirole potentiated the teratogenic effects of l-dopa when these drugs were administered in combination [see data] . in the u.s. general population, the estimated ba
treximet sumatriptan and naproxen sodium tablet film coated
glaxosmithkline llc - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan 85 mg
promacta eltrombopag olamine tablet film coated
glaxosmithkline llc - eltrombopag olamine (unii: 4u07f515lg) (eltrombopag - unii:s56d65xj9g) - eltrombopag 25 mg
zofran- ondansetron hydrochloride solution zofran odt- ondansetron hydrochloride tablet, orally disintegrating zofran- ondan
glaxosmithkline llc - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 4 mg in 5 ml - zofran® is indicated for the prevention of nausea and vomiting associated with: zofran is also indicated for the prevention of postoperative nausea and/or vomiting. zofran is contraindicated in patients: risk summary available data do not reliably inform the association of zofran and adverse fetal outcomes. published epidemiological studies on the association between ondansetron and fetal outcomes have reported inconsistent findings and have important methodological limitations hindering interpretation [see data ]. reproductive studies in rats and rabbits did not show evidence of harm to the fetus when ondansetron was administered during organogenesis at approximately 6 and 24 times the maximum recommended human oral dose of 24 mg/day, based on body surface area, respectively [see data ]. the background risk of major birth defects and miscarriage for the indicated population is unknown. in the us general population, the estimated background risk of major birth defects and miscarriages in clinically recognize
tykerb lapatinib tablet
glaxosmithkline llc - lapatinib ditosylate (unii: g873gx646r) (lapatinib - unii:0vua21238f) - lapatinib 250 mg
tafinlar dabrafenib capsule
glaxosmithkline llc - dabrafenib mesylate (unii: b6dc89i63e) (dabrafenib - unii:qgp4ha4g1b) - dabrafenib 50 mg
votrient pazopanib hydrochloride tablet film coated
glaxosmithkline llc - pazopanib hydrochloride (unii: 33y9anm545) (pazopanib - unii:7rn5dr86ck) - pazopanib 200 mg
hycamtin topotecan hydrochloride capsule
glaxosmithkline llc - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan 0.25 mg
ceftin cefuroxime axetil powder for suspension
glaxosmithkline llc - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 125 mg in 5 ml